About 19 million American adults consume dietary fish oil supplements. These supplements, which primarily consist of the omega-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid, are widely used as a remedy for chronic diseases. However, the effects of EPA and DHA supplementation on cancer risk have been inconsistent.
In a recent multi-institutional clinical trial, 71% of patients who received the immunotherapy drug pembrolizumab, an anti-PD-1 immune checkpoint inhibitor, before surgery had no detectable cancer remaining at the time of surgery.
